Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined azelastine/fluticasone versus single-agent nasal sprays in children with adenoid hypertrophy
IRCT20200718048126N2Phase 3Recruiting
- Sponsor
- Guilan University of Medical Sciences
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of azelastine, fluticasone and azelastine + fluticasone in adenoidal hypertrophy (3 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Change in clinical symptom severity and Change in adenoid size. Started Oct 2026; status: recruiting.
02
Drugs
azelastinefluticasoneazelastine + fluticasone
03
Conditions
adenoidal hypertrophy
Beyond the preview
Go deeper on IRCT20200718048126N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200718048126N2.